Biotricity Stock Story


USD 1.22  0.12  10.91%   

My story will break down Biotricity. I will address few reasons this entity was abused by investors due to the current market volatility. Biotricity is currently traded for 1.60. The entity has historical hype elasticity of 0.01. The average price elasticity to hype of competition is about -0.92. The firm is forecasted to increase in value after the next headline, with the price going to jump to 1.76. The current volatility of media hype impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price jump on the next news is forecasted to be 0.57%, whereas the daily expected return is currently at -0.13%. The volatility of related hype on Biotricity is about 108.59% with expected price after next announcement by competition of 0.68 Given the investment horizon of 90 days the next forecasted press release will be in about 3 days.
Published over a month ago
View all stories for Biotricity | View All Stories

Biotricity Sentiment by News Outlets

benzinga news
prnewswire News
Macroaxis News:

Should I hold on to my Biotricity (NASDAQ:BTCY) position?

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biotricity has an asset utilization ratio of 60818.18 percent. This suggests that the company is making $608.18 for each dollar of assets. An increasing asset utilization means that Biotricity is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Biotricity stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Biotricity, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Biotricity based on Biotricity hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Biotricity's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Biotricity's related companies.

Watch out for price decline

Please consider monitoring Biotricity on a daily basis if you are holding a position in it. Biotricity is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Biotricity stock to be traded above the $1 level to remain listed. If Biotricity stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

Use Technical Analysis to project Biotricity expected Price

Biotricity technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Biotricity technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Biotricity trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How does Biotricity utilize its cash?

To perform a cash flow analysis of Biotricity, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biotricity is receiving and how much cash it distributes out in a given period. The Biotricity cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Biotricity Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Biotricity reported Net Cash Flow from Operations of (15.16 Million) in 2021

Acquisition by Norman Betts of 54348 shares of Biotricity subject to Rule 16b-3

Legal trades by Biotricity insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biotricity insider trading alert for grant of common stock by Norman Betts, the corporate stakeholder, on 6th of December 2021. This event was filed by Biotricity Inc with SEC on 2021-12-06. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Biotricity valued reasonably by the market?

Biotricity price slide over the last few months could raise concerns from investors as the firm is trading at a share price of 1.60 on 55,436 in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in June. However, diversifying your holdings with Biotricity or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.65. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Biotricity partners.
 2019 2020 2021 2022 (projected)
Revenues USD1.42 M3.38 M3.89 M4.2 M
Revenues1.42 M3.38 M3.89 M4.2 M

Cost of Revenue Breakdown

Biotricity Cost of Revenue yearly trend continues to be fairly stable with very little volatility. Cost of Revenue will likely drop to about 1.7 M in 2022. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Biotricity Cost of Revenue is fairly stable at the moment as compared to the past year. Biotricity reported Cost of Revenue of 2.15 Million in 2021
20201.87 Million
20212.15 Million
20221.74 Million

Anything left for Biotricity after the slide?

Biotricity information ratio is up to 0.0. Biotricity is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biotricity independently to ensure intended market timing strategies are aligned with expectations about Biotricity volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biotricity's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biotricity's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Biotricity Implied Volatility

Biotricity's implied volatility exposes the market's sentiment of Biotricity stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Biotricity's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Biotricity stock will not fluctuate a lot when Biotricity's options are near their expiration.

The Bottom Line

While some other firms in the medical devices industry are either recovering or due for a correction, Biotricity may not be as strong as the others in terms of longer-term growth potentials. While some investors may not share our view, we believe it may be a good time to increase your existing holdings in Biotricity as the risk-reward trade off is appealing enough to hold a position. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biotricity.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Biotricity. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to